1Guillaume P,Amaury H.Pharmacokinetics of DTPA entrapped in conventional and long-circulating liposomes of different size for plutonium decorporation[J].J Controlled Release,2005,110 (18):177-188.
2Awasthi VD,Garcia D,Goins BA.Circulation and biodistribution profiles of long-circulating PEG liposomes of various sizes in rabbits[J].Int J Pharm,2003,253(1-2):121-132.
3Kawahara K,Sekiguchi A,Kiyoki E.Effect of TRX-liposomes size on their prolonged circulation in rats[J].Chem Pharm Bull (Tokyo),2003,51(3):336-338.
4Harashima H,Kiwada H.Liposomal targeting and drug delivery:kinetic consideration[J].Adv Drug Deliv,1996,19(1):425-444.
5Litzinger D,Buiting A,Rooijen N.Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes[J].Biochim,1994,1190:99-107.
6Oku N.In vivo trafficking of long-circulating liposomes in tumor-bearing mice determined by positron emission tomography[J].Biopharm Drug Dispos,1996,17:435-441.
7Papahadjopoulos D,Allen TM,Gabizon E.Sterically stabiliz liposomes:improvements in pharmacokinetics and antitumortherapeutic efficacy[J].Proc Natl Acad Sci USA,1991,88:11460-11464.
8Liu D,Mori A,Huang L.Role of liposome size and RES compleblockade in controlling biodistribution and tumor uptake of GM1-containing liposomes[J].Biochim Biophys Acta,1992,1104:95-101.
9Nagayasu A,Uchiyama K,Nishida T.Is control of distribution of liposomes between tumors and bone marrow possible?[J].Biochim Biophys Acta,1996,1278:29-34.
10Zou Y,Ling YH,Reddy S.Effects of vesicle size and lipid composition in the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes[J].Int J Cancer,1995,61:666-671.
5YRNG X,H WEN,W L LU,et al Dual -targeting daunoru- bicin lipesomes improve the therapeutic efficacy of brain glioma in animals [ J ]. J Control Release, 2010. 141 ( 2 ) : 183 - 192.
6KIERAN M W, D WALKER, D FRAPPAZ, et al Brain tumors:from childhood through adolescence into adulthood [J]. J Clin Oncol,2010. 28(32):4783 -4789.
7M1TTAL S,S PRADHAN ,T SRIVASAVA,et al Recent ad- vances in targeted therapy for glioblastoma[ J ]. Expert Rev Neurother, 2015.15(8) :935 -946.
8PARDRIDGE W M. Why is the global CNS pharmaceutical market so under - penetrated [ J ]. Drug Discov Today, 2002. 7(1) : 5 -7.
9PARDRIDGE W M. The blood- brain barrier:bottleneck in brain drug development[J]. NeuroRx,2005. 2(1) :3 -14.
10GAILLARD P J. C C VISSER, C C. APPELDOORN,et al. Targeted blood - to - brain drug delivery 10 key de- velopment criteria [ J ]. Curr Pharm Biotechnol, 2012. 13 (12) :2328 -2339.
